View ValuationRibomic 将来の成長Future 基準チェック /06現在、 Ribomicの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長39.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Feb 11Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.お知らせ • Nov 12Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.お知らせ • May 26Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2022. For the year, the company expected operating revenue of JPY 80 million, operating loss of JPY 2,495 million, loss of JPY 2,393 million and loss per share of JPY 85.75.すべての更新を表示Recent updatesReported Earnings • May 19Full year 2026 earnings released: JP¥23.06 loss per share (vs JP¥25.19 loss in FY 2025)Full year 2026 results: JP¥23.06 loss per share. Net loss: JP¥1.15b (loss widened 13% from FY 2025).お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 23, 2026Ribomic Inc., Annual General Meeting, Jun 23, 2026.New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥750k revenue, or US$4.8k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥5.38b market cap, or US$34.1m).New Risk • Jan 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥4.83b market cap, or US$30.6m).分析記事 • Dec 08We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Dec 02Ribomic Inc. to Report Q3, 2026 Results on Feb 12, 2026Ribomic Inc. announced that they will report Q3, 2026 results on Feb 12, 2026New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (JP¥4.21b market cap, or US$27.1m).お知らせ • Oct 07Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and OlderRIBOMIC Inc. has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed the trial and demonstrated a positive impact of the test drug on the patient growth rate. In this Phase 2 clinical trial, both Cohort 1 and Cohort 2 received the same total dose of the investigational drug. Cohort 1 Note 2, which was completed earlier, consisted of a group receiving weekly subcutaneous injection of a low dose (0.3 mg/kg). In contrast, Cohort 2 consists of a high dose (0.6 mg/kg), administered every other week. The trial's objective is to confirm the efficacy, safety and durability of umedaptanib Pegol. In Cohort 2, all 6 subjects completed the trial, and 5 subjects showed increased height growth rate, with 2 showing significant increases of +5.0 cm/year and +2.0 cm/year. The results for these 4 subjects with markedly increased height growth exceeded the average height growth rate of +1.7 cm/year for Voxzogo®? (vosoritide, manufactured by BioMarin, administered subcutaneously daily), which is currently approved as an ACH treatment. Furthermore, the mean height growth rates for Cohorts 1 and 2 were +1.5 cm/year and +1.4 cm/year, respectively, which are comparable to those of Voxzogo®?. No safety concerns arose throughout the Phase 2 clinical trial. These results demonstrate the efficacy, safety and durability the efficacy of umedaptanib squareol in Phase 2 clinical trials, successfully establishing proof-of-concept (POC) as an ACH treatment. The study demonstrated that increasing the total dose allows for extending the dosing interval. Umedaptanib pegol is expected to achieve results comparable to those of Voxzog®? with biweekly or weekly dosing. This should significantly benefit pediatric ACH patients, who are expected to require long-term treatment. Based on the successful completion of the Phase 2 trial, the company are planning a Phase 3 clinical trial to further verify the efficacy of umedapt anib pegol as an ACH treatment. Previous nonclinical studies using ACH animal models demonstrated that bone elongation rates increased proportionally with the dose of the drug. Therefore, the Phase 3 trial will increase the weekly subcutaneous dose of umedaptanib peol to approximately 1 mg/kg and lower the participating pediatric patients' ages to around two years. This approach is expected to yield significantly improved treatment outcomes compared to those of currently approved drugs. After confirming safety and tolerability, the dosing interval will be changed to once weekly for 26 weeks (total dosing period: 34 weeks). Note3 A study to obtain baseline clinical data, including pre-treatment height growth, for pediatric ACH patients. This data will enable efficacy evaluation in the Phase 2 clinical trial and facilitate appropriate subject selection (total observation period: 26 weeks). Note4 Kimura T, --- Nakamura Y, Ozono K, Krejci P. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia.お知らせ • Sep 27Ribomic Inc. to Report Q2, 2026 Results on Oct 14, 2025Ribomic Inc. announced that they will report Q2, 2026 results on Oct 14, 2025Reported Earnings • Aug 14First quarter 2026 earnings released: JP¥5.09 loss per share (vs JP¥6.97 loss in 1Q 2025)First quarter 2026 results: JP¥5.09 loss per share (improved from JP¥6.97 loss in 1Q 2025). Net loss: JP¥227.0m (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Jul 02Ribomic Inc. to Report Q1, 2026 Results on Aug 12, 2025Ribomic Inc. announced that they will report Q1, 2026 results on Aug 12, 2025分析記事 • Jun 18Companies Like Ribomic (TSE:4591) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 24, 2025Ribomic Inc., Annual General Meeting, Jun 24, 2025.お知らせ • Mar 01Ribomic Inc. to Report Fiscal Year 2025 Results on May 13, 2025Ribomic Inc. announced that they will report fiscal year 2025 results on May 13, 2025分析記事 • Feb 12We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Feb 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 5.8% per year over the past 5 years. Revenue is less than US$1m (JP¥2.0m revenue, or US$13k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥3.50b market cap, or US$22.7m).お知らせ • Jan 03Ribomic Inc. to Report Q3, 2025 Results on Feb 12, 2025Ribomic Inc. announced that they will report Q3, 2025 results on Feb 12, 2025分析記事 • Oct 30Companies Like Ribomic (TSE:4591) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Oct 06Ribomic Inc. to Report Q2, 2025 Results on Nov 12, 2024Ribomic Inc. announced that they will report Q2, 2025 results on Nov 12, 2024お知らせ • Aug 03Ribomic Inc. Announces Completion of Patient Enrollment in Early Phase Ii Study of Umedaptanib Pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase Ii Clinical StudyRIBOMIC Inc. announced that 13 patients have been enrolled in an observational study 1 of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (5-14 years old) with Achondroplasia in an early phase II study. A low-dose subcutaneous study (Cohort1) to evaluate the efficacy and safety of umedaptanib pegol in six patients who have completed the observational study is ongoing and is expected to be completed in November of this year. These patients will continue in the extension study and three have already completed Cohort 1 and entered the extension study. RIBOMIC also announced that the first patient in a high-dose subcutaneous study (Cohort 2) of umedaptanib pegol has been dosed in patients who have completed the observational study has been administered. No safety concerns have been identified in the ongoing early phase II clinical study and extension study, including this case.分析記事 • Jul 02We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • Jun 28Ribomic Inc. to Report Q1, 2025 Results on Aug 09, 2024Ribomic Inc. announced that they will report Q1, 2025 results on Aug 09, 2024New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (JP¥3.07b market cap, or US$19.6m).お知らせ • May 16Ribomic Inc., Annual General Meeting, Jun 25, 2024Ribomic Inc., Annual General Meeting, Jun 25, 2024.New Risk • May 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (JP¥62m revenue, or US$403k). Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (JP¥3.14b market cap, or US$20.4m).お知らせ • Mar 28Ribomic Inc. to Report Fiscal Year 2024 Results on May 14, 2024Ribomic Inc. announced that they will report fiscal year 2024 results on May 14, 2024お知らせ • Mar 07Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.On March 7, 2024, Ribomic Inc. closed the transaction.お知らせ • Feb 21Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.Ribomic Inc. announces private placement of 17th stock acquisition rights of 89,196 stock acquisition rights at an issue price of JPY 47 per stock acquisition rights for gross proceeds of JPY 4,192,212 on February 20, 2024. The stock acquisition right will be convertible into 8,919,600 shares at an initial exercise price of JPY 102 per share. Exercise period of stock acquisition rights for March 8, 2024 to March 5, 2022. The transaction included participation from SMBC Nikko Securities. The transaction is expected to close on March 7, 2024.お知らせ • Jan 13Ribomic Inc. to Report Q3, 2024 Results on Feb 13, 2024Ribomic Inc. announced that they will report Q3, 2024 results on Feb 13, 2024お知らせ • Dec 05RIBOMIC Phase I and II Data Published in the EyeRIBOMIC Inc. announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2. TOFU is a randomized, double-masked study assessing the efficacy of intravitreal uMedaptanib pegol monotherapy or in combination with Eylea®?, compared to Eylea®? monotherapy in 86 subjects with anti-VEGF pretreated nAMD. RAMEN is an extension study of TOFU, in which 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedapt anib pegol. TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib Pegol in five treatment-naive nAMD patients. Throughout these studies umedaptanib pegOL was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment. Striking improvements in visual acuity and anatomy were observed in some of the treatment naive patients. In nAMD patients with a long history of anti-VEGF therapy, umedaptanib pegal showed no additional benefit of monotherapy or the combination over Eylea®?. Nevertheless, the pre-existing fibrosis remained stable without worsening in these studies. Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®?) to umedaptanib pegola in the RAMEN study. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.Reported Earnings • Nov 14First half 2024 earnings releasedFirst half 2024 results: Net loss: JP¥554.9m (loss narrowed 37% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 28Ribomic Inc. to Report Q2, 2024 Results on Nov 13, 2023Ribomic Inc. announced that they will report Q2, 2024 results on Nov 13, 2023New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (JP¥63m revenue, or US$431k). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥5.17b market cap, or US$35.4m).Reported Earnings • Aug 11First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: JP¥335.0m (loss narrowed 45% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 30Ribomic Inc. to Report Q1, 2024 Results on Aug 10, 2023Ribomic Inc. announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • May 13Ribomic Inc., Annual General Meeting, Jun 27, 2023Ribomic Inc., Annual General Meeting, Jun 27, 2023.Reported Earnings • May 13Full year 2023 earnings releasedFull year 2023 results: Net loss: JP¥1.65b (loss narrowed 1.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥18.86 loss per share (vs JP¥12.37 loss in 3Q 2022)Third quarter 2023 results: JP¥18.86 loss per share (further deteriorated from JP¥12.37 loss in 3Q 2022). Net loss: JP¥598.0m (loss widened 72% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 11Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.お知らせ • Dec 02Ribomic Inc. to Report Q3, 2023 Results on Feb 10, 2023Ribomic Inc. announced that they will report Q3, 2023 results on Feb 10, 2023お知らせ • Nov 28Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia PatientsRibomic Inc. announced that the first case has been registered at Tokyo Medical and Dental University Hospital for an observational study to obtain basic clinical data including height growth and to select appropriate subjects for continuously scheduled RBM-007 early phase 2 study in Achondroplasia patients. Furthermore, RIBOMIC has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) to conduct an early Phase 2 study of exploratory investigation for the safety and efficacy of RBM-007 in achondroplasia pediatric patients, as well as following extension study. Therefore, RIBOMIC is planning to proceed with those studies following the observational study.Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)Second quarter 2023 results: JP¥9.28 loss per share (improved from JP¥15.44 loss in 2Q 2022). Net loss: JP¥265.0m (loss narrowed 39% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Outside Director Toshiaki Nishihata was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)Second quarter 2023 results: JP¥9.28 loss per share (improved from JP¥15.44 loss in 2Q 2022). Net loss: JP¥265.0m (loss narrowed 39% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 12Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.お知らせ • Oct 13Ribomic Inc. announced that it expects to receive ¥5.1372 million in fundingRibomic Inc. announced a private placement of 71,350 stock acquisition rights to be issued at ¥72 per right for proceeds of ¥5,137,200 on October 11, 2022. The rights will convert into 7,135,000 shares, 100 shares per right at an initial exercise price of ¥181. The exercise period of the rights is from October 28, 2022 to October 27, 2025. The transaction will include participation from SMBC Nikko Securities. The transaction is expected to close on October 27, 2022.お知らせ • Sep 28Ribomic Inc. to Report Q2, 2023 Results on Nov 11, 2022Ribomic Inc. announced that they will report Q2, 2023 results on Nov 11, 2022Reported Earnings • Aug 12First quarter 2023 earnings released: JP¥21.46 loss per share (vs JP¥12.04 loss in 1Q 2022)First quarter 2023 results: JP¥21.46 loss per share (down from JP¥12.04 loss in 1Q 2022). Net loss: JP¥613.0m (loss widened 82% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 01RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug EfficacyRIBOMIC Inc. announced the publication of the preclinical data of its anti-TGF-1 aptamer demonstrating the enhancement of efficacy of anti-cancer drug, gefitinib, in non-small cell lung cancer xenograft model. The aptamer is being developed in collaboration with Project Associate Professor Masaki Takahashi at Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo.お知らせ • Jun 24Ribomic Inc. to Report Q1, 2023 Results on Aug 09, 2022Ribomic Inc. announced that they will report Q1, 2023 results on Aug 09, 2022Reported Earnings • May 17Full year 2022 earnings released: JP¥59.92 loss per share (vs JP¥46.16 loss in FY 2021)Full year 2022 results: JP¥59.92 loss per share (down from JP¥46.16 loss in FY 2021). Net loss: JP¥1.68b (loss widened 42% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 28, 2022Ribomic Inc., Annual General Meeting, Jun 28, 2022.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Outside Director Toshiaki Nishihata was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 19Ribomic Inc. Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of AchondroplasiaRibomic Inc. announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The purpose of the observational study is to obtain clinical basic data, including height growth, and to select subjects for the early phase II study. If there is no comment from PMDA for 14 days after submission, the observational study will be initiated.お知らせ • Apr 08Ribomic Inc. to Report Fiscal Year 2022 Results on May 13, 2022Ribomic Inc. announced that they will report fiscal year 2022 results on May 13, 2022Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥12.36 loss per share (down from JP¥9.49 loss in 3Q 2021). Net loss: JP¥346.6m (loss widened 31% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Feb 06Ribomic Inc. to Report Q3, 2022 Results on Feb 14, 2022Ribomic Inc. announced that they will report Q3, 2022 results on Feb 14, 2022お知らせ • Dec 29RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular DegenerationRIBOMIC Inc. announced the topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD).TOFU study is a double-masked, randomized, active-controlled Phase 2 trial (n=86) evaluating the efficacy and safety of RBM-007 monotherapy and RBM-007 in combination with Eylea® compared to Eylea® monotherapy in patients with wAMD who are previously treated with Standard of Care (anti-VEGF drugs).As a result of the analysis, RBM-007 monotherapy or RBM-007 in combination with Eylea® did not demonstrate vision improvement over Eylea® monotherapy in this patient population. On the other hand, in treatment naïve wAMD patients, preliminary interim data from the ongoing phase 2 TEMPURA investigator sponsored trial evaluating the safety and efficacy of RBM-007 monotherapy are showing improvement in vision and retinal anatomy. Additional analyses of secondary endpoints of TOFU are ongoing. The company is planning to share the detailed results together with those from its RAMEN extension study and TEMPURA study as full dataset.Reported Earnings • Nov 10Second quarter 2022 earnings released: JP¥15.44 loss per share (vs JP¥11.57 loss in 2Q 2021)Second quarter 2022 results: Net loss: JP¥431.0m (loss widened 35% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥12.04 loss per share (vs JP¥13.82 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥336.0m (loss widened 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Aug 06Ribomic Inc. Completes Patient Enrollment of Its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (Tofu Study)RIBOMIC Inc. announced that the patient enrollment is completed in Phase 2 trial (TOFU) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary. The Company expects topline TOFU data to become available during the first quarter of 2022. RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including wet AMD., The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD. In addition to the TOFU study, it is being investigated as a monotherapy in an extension trial RAMEN (NCT04640272) and in treatment naïve wet AMD patients in an IST, the TEMPURA study (NCT04895293) A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 monotherapy and RBM-007 in Combination with Eylea® Compared to Eylea® Monotherapy in Subjects with Wet Age-related Macular Degeneration (TOFU Study) is Phase 2 Study assessing the safety, efficacy and durability of RBM-007.お知らせ • Jul 14Ribomic Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in Treatment Naive Wet AMD PatientsRibomic Inc. announced that the first subject has been dosed in a phase 2 investigator sponsored trial (IST) - named 'TEMPURA Study' for wet AMD. The TEMPURA IST (NCT04895293) is being conducted by Dr. Raj K. Maturi M.D. P.C at the Midwest Eye Institute, Indiana. The open labelled clinical trial is enrolling patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. The study has been designed to assess the safety and efficacy of intravitreal injections of RBM-007 in treatment naïve patients. RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including wet AMD. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD. It is currently being investigated as a monotherapy and in combination with Eylea in patients with wet AMD in a P2 clinical trial (TOFU study NCT04200248) and an extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 (RAMEN Study NCT04640272).お知らせ • May 26Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2022. For the year, the company expected operating revenue of JPY 80 million, operating loss of JPY 2,495 million, loss of JPY 2,393 million and loss per share of JPY 85.75.お知らせ • May 22Ribomic Inc. Announces Completion of Its Phase I Trial of RBM-007 for the Treatment of AchondroplasiaRibomic Inc. announced the completion of its Phase I study of RBM-007 for the treatment of achondroplasia. The study results will be reported after a detailed analysis of the trial data. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.Reported Earnings • May 16Full year 2021 earnings released: JP¥46.16 loss per share (vs JP¥53.62 loss in FY 2020)Full year 2021 results: Net loss: JP¥1.19b (loss widened 39% from FY 2020). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥9.49 loss per share (vs JP¥15.71 loss in 3Q 2020)Third quarter 2021 results: Net loss: JP¥265.0m (loss widened 4.7% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Feb 11Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and DevelopmentRibomic Inc. and ASKA Pharmaceutical Co., Ltd. announced that they executed a multi-year joint research and development agreement for drug discovery research and development targeting specific hormone receptors with the aim of discovering new drugs. In this research, they concluded this agreement due to matching the intention of RIBOMIC, a medical discovery platform bio-venture, developing aptamer which is a kind of Nucleic Acid medicines, and ASKA holding the management vision of "becoming highly competitive specialty pharma company," and actively promoting the development based on new products. ASKA has been focusing on the development of pharmaceutical products for diseases in the field of obstetrics and gynecology, and aims to create aptamer pharmaceuticals that act on certain hormone receptors that play a crucial role in the field, by using RiboART System, RIBOMIC's basic drug discovery technology. With the conclusion of this agreement, ASKA will pay research expenditures to RIBOMIC on a step-by-step basis. RIBOMIC will also be entitled to an upfront payment for achievement of milestones in accordance with certain outcomes of the joint research. In addition, specific achievement conditions and amounts will not be disclosed under the contract. The impact of this transaction on RIBOMIC and ASKA's results for FY2020 will be minor.お知らせ • Feb 02Ribomic Inc. Announces Completion of 50% of Enrollment of its Phase 2 Clinical Trial for Wet Age-Related Macular Degeneration (Tofu Study)Ribomic Inc. announced that it has completed subject enrollment of more than 50% of the ongoing Phase 2 trial (TOFU) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary. Despite COVID-19, RIBOMIC remains on track to complete TOFU by the end of 2021 as had been planned before the pandemic. In addition, the enrollment of the Phase 2 extension study (RAMEN) is also progressing well. Continued interest from clinical investigators in this extension study fueling the momentum required for the RAMEN study to also be completed by the end of 2021.Is New 90 Day High Low • Dec 22New 90-day low: JP¥352The company is down 33% from its price of JP¥522 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.お知らせ • Jun 29Ribomic Inc. to Report Q1, 2021 Results on Aug 07, 2020Ribomic Inc. announced that they will report Q1, 2021 results on Aug 07, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ribomic は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4591 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20263-1,145-1,120-1,110N/A12/31/20251-1,042N/AN/AN/A9/30/2025N/A-1,053-1,033-1,023N/A6/30/20251-1,036-1,032-1,011N/A3/31/20252-1,018-1,028-996N/A12/31/20242-962N/AN/AN/A9/30/20242-949-892-860N/A6/30/20241-944N/AN/AN/A3/31/2024N/A-1,024-954-932N/A12/31/202362-979N/AN/AN/A9/30/202362-1,329-1,418-1,396N/A6/30/202363-1,374N/AN/AN/A3/31/202365-1,653-1,731-1,708N/A12/31/202276-2,046N/AN/AN/A9/30/202278-1,795-1,759-1,729N/A6/30/202280-1,961N/AN/AN/A3/31/202280-1,684-1,509-1,499N/A12/31/202193-1,448N/AN/AN/A9/30/202192-1,366-1,525-1,523N/A6/30/202191-1,255N/AN/AN/A3/31/202191-1,187-1,150-1,149N/A12/31/2020121-1,056N/AN/AN/A9/30/2020122-1,044-848-801N/A6/30/2020122-903N/AN/AN/A3/31/2020121-855-948-902N/A12/31/201912-804N/AN/AN/A9/30/201910-761N/A-776N/A6/30/20198-779N/AN/AN/A3/31/20197-836N/A-830N/A12/31/201814-919N/AN/AN/A9/30/201830-904N/A-798N/A6/30/201847-867N/AN/AN/A3/31/201864-753N/A-694N/A12/31/201768-714N/AN/AN/A9/30/201777-700N/A-757N/A6/30/201786-661N/AN/AN/A3/31/201793-646N/A-706N/A12/31/2016101-459N/AN/AN/A9/30/2016103-393N/A-321N/A6/30/2016106-371N/AN/AN/A3/31/2016121-323N/A-324N/A12/31/2015149-365N/AN/AN/A9/30/2015173-317N/A-322N/A6/30/2015197-286N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4591の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4591の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4591の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4591の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4591の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4591の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 16:05終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ribomic Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kazuaki HashiguchiDaiwa Securities Co. Ltd.Kiyokazu YamazakiIchiyoshi Research Institute Inc.
お知らせ • Feb 11Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.
お知らせ • Nov 12Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.
お知らせ • May 26Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2022. For the year, the company expected operating revenue of JPY 80 million, operating loss of JPY 2,495 million, loss of JPY 2,393 million and loss per share of JPY 85.75.
Reported Earnings • May 19Full year 2026 earnings released: JP¥23.06 loss per share (vs JP¥25.19 loss in FY 2025)Full year 2026 results: JP¥23.06 loss per share. Net loss: JP¥1.15b (loss widened 13% from FY 2025).
お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 23, 2026Ribomic Inc., Annual General Meeting, Jun 23, 2026.
New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥750k revenue, or US$4.8k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥5.38b market cap, or US$34.1m).
New Risk • Jan 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥4.83b market cap, or US$30.6m).
分析記事 • Dec 08We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Dec 02Ribomic Inc. to Report Q3, 2026 Results on Feb 12, 2026Ribomic Inc. announced that they will report Q3, 2026 results on Feb 12, 2026
New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (JP¥4.21b market cap, or US$27.1m).
お知らせ • Oct 07Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and OlderRIBOMIC Inc. has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed the trial and demonstrated a positive impact of the test drug on the patient growth rate. In this Phase 2 clinical trial, both Cohort 1 and Cohort 2 received the same total dose of the investigational drug. Cohort 1 Note 2, which was completed earlier, consisted of a group receiving weekly subcutaneous injection of a low dose (0.3 mg/kg). In contrast, Cohort 2 consists of a high dose (0.6 mg/kg), administered every other week. The trial's objective is to confirm the efficacy, safety and durability of umedaptanib Pegol. In Cohort 2, all 6 subjects completed the trial, and 5 subjects showed increased height growth rate, with 2 showing significant increases of +5.0 cm/year and +2.0 cm/year. The results for these 4 subjects with markedly increased height growth exceeded the average height growth rate of +1.7 cm/year for Voxzogo®? (vosoritide, manufactured by BioMarin, administered subcutaneously daily), which is currently approved as an ACH treatment. Furthermore, the mean height growth rates for Cohorts 1 and 2 were +1.5 cm/year and +1.4 cm/year, respectively, which are comparable to those of Voxzogo®?. No safety concerns arose throughout the Phase 2 clinical trial. These results demonstrate the efficacy, safety and durability the efficacy of umedaptanib squareol in Phase 2 clinical trials, successfully establishing proof-of-concept (POC) as an ACH treatment. The study demonstrated that increasing the total dose allows for extending the dosing interval. Umedaptanib pegol is expected to achieve results comparable to those of Voxzog®? with biweekly or weekly dosing. This should significantly benefit pediatric ACH patients, who are expected to require long-term treatment. Based on the successful completion of the Phase 2 trial, the company are planning a Phase 3 clinical trial to further verify the efficacy of umedapt anib pegol as an ACH treatment. Previous nonclinical studies using ACH animal models demonstrated that bone elongation rates increased proportionally with the dose of the drug. Therefore, the Phase 3 trial will increase the weekly subcutaneous dose of umedaptanib peol to approximately 1 mg/kg and lower the participating pediatric patients' ages to around two years. This approach is expected to yield significantly improved treatment outcomes compared to those of currently approved drugs. After confirming safety and tolerability, the dosing interval will be changed to once weekly for 26 weeks (total dosing period: 34 weeks). Note3 A study to obtain baseline clinical data, including pre-treatment height growth, for pediatric ACH patients. This data will enable efficacy evaluation in the Phase 2 clinical trial and facilitate appropriate subject selection (total observation period: 26 weeks). Note4 Kimura T, --- Nakamura Y, Ozono K, Krejci P. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia.
お知らせ • Sep 27Ribomic Inc. to Report Q2, 2026 Results on Oct 14, 2025Ribomic Inc. announced that they will report Q2, 2026 results on Oct 14, 2025
Reported Earnings • Aug 14First quarter 2026 earnings released: JP¥5.09 loss per share (vs JP¥6.97 loss in 1Q 2025)First quarter 2026 results: JP¥5.09 loss per share (improved from JP¥6.97 loss in 1Q 2025). Net loss: JP¥227.0m (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Jul 02Ribomic Inc. to Report Q1, 2026 Results on Aug 12, 2025Ribomic Inc. announced that they will report Q1, 2026 results on Aug 12, 2025
分析記事 • Jun 18Companies Like Ribomic (TSE:4591) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 24, 2025Ribomic Inc., Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 01Ribomic Inc. to Report Fiscal Year 2025 Results on May 13, 2025Ribomic Inc. announced that they will report fiscal year 2025 results on May 13, 2025
分析記事 • Feb 12We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Feb 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 5.8% per year over the past 5 years. Revenue is less than US$1m (JP¥2.0m revenue, or US$13k). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥3.50b market cap, or US$22.7m).
お知らせ • Jan 03Ribomic Inc. to Report Q3, 2025 Results on Feb 12, 2025Ribomic Inc. announced that they will report Q3, 2025 results on Feb 12, 2025
分析記事 • Oct 30Companies Like Ribomic (TSE:4591) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Oct 06Ribomic Inc. to Report Q2, 2025 Results on Nov 12, 2024Ribomic Inc. announced that they will report Q2, 2025 results on Nov 12, 2024
お知らせ • Aug 03Ribomic Inc. Announces Completion of Patient Enrollment in Early Phase Ii Study of Umedaptanib Pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase Ii Clinical StudyRIBOMIC Inc. announced that 13 patients have been enrolled in an observational study 1 of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (5-14 years old) with Achondroplasia in an early phase II study. A low-dose subcutaneous study (Cohort1) to evaluate the efficacy and safety of umedaptanib pegol in six patients who have completed the observational study is ongoing and is expected to be completed in November of this year. These patients will continue in the extension study and three have already completed Cohort 1 and entered the extension study. RIBOMIC also announced that the first patient in a high-dose subcutaneous study (Cohort 2) of umedaptanib pegol has been dosed in patients who have completed the observational study has been administered. No safety concerns have been identified in the ongoing early phase II clinical study and extension study, including this case.
分析記事 • Jul 02We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • Jun 28Ribomic Inc. to Report Q1, 2025 Results on Aug 09, 2024Ribomic Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (JP¥3.07b market cap, or US$19.6m).
お知らせ • May 16Ribomic Inc., Annual General Meeting, Jun 25, 2024Ribomic Inc., Annual General Meeting, Jun 25, 2024.
New Risk • May 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (JP¥62m revenue, or US$403k). Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (JP¥3.14b market cap, or US$20.4m).
お知らせ • Mar 28Ribomic Inc. to Report Fiscal Year 2024 Results on May 14, 2024Ribomic Inc. announced that they will report fiscal year 2024 results on May 14, 2024
お知らせ • Mar 07Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.On March 7, 2024, Ribomic Inc. closed the transaction.
お知らせ • Feb 21Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.Ribomic Inc. announces private placement of 17th stock acquisition rights of 89,196 stock acquisition rights at an issue price of JPY 47 per stock acquisition rights for gross proceeds of JPY 4,192,212 on February 20, 2024. The stock acquisition right will be convertible into 8,919,600 shares at an initial exercise price of JPY 102 per share. Exercise period of stock acquisition rights for March 8, 2024 to March 5, 2022. The transaction included participation from SMBC Nikko Securities. The transaction is expected to close on March 7, 2024.
お知らせ • Jan 13Ribomic Inc. to Report Q3, 2024 Results on Feb 13, 2024Ribomic Inc. announced that they will report Q3, 2024 results on Feb 13, 2024
お知らせ • Dec 05RIBOMIC Phase I and II Data Published in the EyeRIBOMIC Inc. announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2. TOFU is a randomized, double-masked study assessing the efficacy of intravitreal uMedaptanib pegol monotherapy or in combination with Eylea®?, compared to Eylea®? monotherapy in 86 subjects with anti-VEGF pretreated nAMD. RAMEN is an extension study of TOFU, in which 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedapt anib pegol. TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib Pegol in five treatment-naive nAMD patients. Throughout these studies umedaptanib pegOL was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment. Striking improvements in visual acuity and anatomy were observed in some of the treatment naive patients. In nAMD patients with a long history of anti-VEGF therapy, umedaptanib pegal showed no additional benefit of monotherapy or the combination over Eylea®?. Nevertheless, the pre-existing fibrosis remained stable without worsening in these studies. Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®?) to umedaptanib pegola in the RAMEN study. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.
Reported Earnings • Nov 14First half 2024 earnings releasedFirst half 2024 results: Net loss: JP¥554.9m (loss narrowed 37% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 28Ribomic Inc. to Report Q2, 2024 Results on Nov 13, 2023Ribomic Inc. announced that they will report Q2, 2024 results on Nov 13, 2023
New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (JP¥63m revenue, or US$431k). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥5.17b market cap, or US$35.4m).
Reported Earnings • Aug 11First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: JP¥335.0m (loss narrowed 45% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 30Ribomic Inc. to Report Q1, 2024 Results on Aug 10, 2023Ribomic Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • May 13Ribomic Inc., Annual General Meeting, Jun 27, 2023Ribomic Inc., Annual General Meeting, Jun 27, 2023.
Reported Earnings • May 13Full year 2023 earnings releasedFull year 2023 results: Net loss: JP¥1.65b (loss narrowed 1.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥18.86 loss per share (vs JP¥12.37 loss in 3Q 2022)Third quarter 2023 results: JP¥18.86 loss per share (further deteriorated from JP¥12.37 loss in 3Q 2022). Net loss: JP¥598.0m (loss widened 72% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 11Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.
お知らせ • Dec 02Ribomic Inc. to Report Q3, 2023 Results on Feb 10, 2023Ribomic Inc. announced that they will report Q3, 2023 results on Feb 10, 2023
お知らせ • Nov 28Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia PatientsRibomic Inc. announced that the first case has been registered at Tokyo Medical and Dental University Hospital for an observational study to obtain basic clinical data including height growth and to select appropriate subjects for continuously scheduled RBM-007 early phase 2 study in Achondroplasia patients. Furthermore, RIBOMIC has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) to conduct an early Phase 2 study of exploratory investigation for the safety and efficacy of RBM-007 in achondroplasia pediatric patients, as well as following extension study. Therefore, RIBOMIC is planning to proceed with those studies following the observational study.
Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)Second quarter 2023 results: JP¥9.28 loss per share (improved from JP¥15.44 loss in 2Q 2022). Net loss: JP¥265.0m (loss narrowed 39% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Outside Director Toshiaki Nishihata was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)Second quarter 2023 results: JP¥9.28 loss per share (improved from JP¥15.44 loss in 2Q 2022). Net loss: JP¥265.0m (loss narrowed 39% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 12Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects operating revenues of JPY 65 million, operating loss of JPY 2,402 million, loss of JPY 2,294 million or JPY 80.35 per share.
お知らせ • Oct 13Ribomic Inc. announced that it expects to receive ¥5.1372 million in fundingRibomic Inc. announced a private placement of 71,350 stock acquisition rights to be issued at ¥72 per right for proceeds of ¥5,137,200 on October 11, 2022. The rights will convert into 7,135,000 shares, 100 shares per right at an initial exercise price of ¥181. The exercise period of the rights is from October 28, 2022 to October 27, 2025. The transaction will include participation from SMBC Nikko Securities. The transaction is expected to close on October 27, 2022.
お知らせ • Sep 28Ribomic Inc. to Report Q2, 2023 Results on Nov 11, 2022Ribomic Inc. announced that they will report Q2, 2023 results on Nov 11, 2022
Reported Earnings • Aug 12First quarter 2023 earnings released: JP¥21.46 loss per share (vs JP¥12.04 loss in 1Q 2022)First quarter 2023 results: JP¥21.46 loss per share (down from JP¥12.04 loss in 1Q 2022). Net loss: JP¥613.0m (loss widened 82% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 01RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug EfficacyRIBOMIC Inc. announced the publication of the preclinical data of its anti-TGF-1 aptamer demonstrating the enhancement of efficacy of anti-cancer drug, gefitinib, in non-small cell lung cancer xenograft model. The aptamer is being developed in collaboration with Project Associate Professor Masaki Takahashi at Project Division of RNA Medical Science, The Institute of Medical Science, The University of Tokyo.
お知らせ • Jun 24Ribomic Inc. to Report Q1, 2023 Results on Aug 09, 2022Ribomic Inc. announced that they will report Q1, 2023 results on Aug 09, 2022
Reported Earnings • May 17Full year 2022 earnings released: JP¥59.92 loss per share (vs JP¥46.16 loss in FY 2021)Full year 2022 results: JP¥59.92 loss per share (down from JP¥46.16 loss in FY 2021). Net loss: JP¥1.68b (loss widened 42% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • May 14Ribomic Inc., Annual General Meeting, Jun 28, 2022Ribomic Inc., Annual General Meeting, Jun 28, 2022.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Outside Director Toshiaki Nishihata was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 19Ribomic Inc. Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of AchondroplasiaRibomic Inc. announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The purpose of the observational study is to obtain clinical basic data, including height growth, and to select subjects for the early phase II study. If there is no comment from PMDA for 14 days after submission, the observational study will be initiated.
お知らせ • Apr 08Ribomic Inc. to Report Fiscal Year 2022 Results on May 13, 2022Ribomic Inc. announced that they will report fiscal year 2022 results on May 13, 2022
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥12.36 loss per share (down from JP¥9.49 loss in 3Q 2021). Net loss: JP¥346.6m (loss widened 31% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Feb 06Ribomic Inc. to Report Q3, 2022 Results on Feb 14, 2022Ribomic Inc. announced that they will report Q3, 2022 results on Feb 14, 2022
お知らせ • Dec 29RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular DegenerationRIBOMIC Inc. announced the topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD).TOFU study is a double-masked, randomized, active-controlled Phase 2 trial (n=86) evaluating the efficacy and safety of RBM-007 monotherapy and RBM-007 in combination with Eylea® compared to Eylea® monotherapy in patients with wAMD who are previously treated with Standard of Care (anti-VEGF drugs).As a result of the analysis, RBM-007 monotherapy or RBM-007 in combination with Eylea® did not demonstrate vision improvement over Eylea® monotherapy in this patient population. On the other hand, in treatment naïve wAMD patients, preliminary interim data from the ongoing phase 2 TEMPURA investigator sponsored trial evaluating the safety and efficacy of RBM-007 monotherapy are showing improvement in vision and retinal anatomy. Additional analyses of secondary endpoints of TOFU are ongoing. The company is planning to share the detailed results together with those from its RAMEN extension study and TEMPURA study as full dataset.
Reported Earnings • Nov 10Second quarter 2022 earnings released: JP¥15.44 loss per share (vs JP¥11.57 loss in 2Q 2021)Second quarter 2022 results: Net loss: JP¥431.0m (loss widened 35% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥12.04 loss per share (vs JP¥13.82 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥336.0m (loss widened 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06Ribomic Inc. Completes Patient Enrollment of Its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (Tofu Study)RIBOMIC Inc. announced that the patient enrollment is completed in Phase 2 trial (TOFU) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary. The Company expects topline TOFU data to become available during the first quarter of 2022. RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including wet AMD., The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD. In addition to the TOFU study, it is being investigated as a monotherapy in an extension trial RAMEN (NCT04640272) and in treatment naïve wet AMD patients in an IST, the TEMPURA study (NCT04895293) A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 monotherapy and RBM-007 in Combination with Eylea® Compared to Eylea® Monotherapy in Subjects with Wet Age-related Macular Degeneration (TOFU Study) is Phase 2 Study assessing the safety, efficacy and durability of RBM-007.
お知らせ • Jul 14Ribomic Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in Treatment Naive Wet AMD PatientsRibomic Inc. announced that the first subject has been dosed in a phase 2 investigator sponsored trial (IST) - named 'TEMPURA Study' for wet AMD. The TEMPURA IST (NCT04895293) is being conducted by Dr. Raj K. Maturi M.D. P.C at the Midwest Eye Institute, Indiana. The open labelled clinical trial is enrolling patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. The study has been designed to assess the safety and efficacy of intravitreal injections of RBM-007 in treatment naïve patients. RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including wet AMD. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD. It is currently being investigated as a monotherapy and in combination with Eylea in patients with wet AMD in a P2 clinical trial (TOFU study NCT04200248) and an extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 (RAMEN Study NCT04640272).
お知らせ • May 26Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2022. For the year, the company expected operating revenue of JPY 80 million, operating loss of JPY 2,495 million, loss of JPY 2,393 million and loss per share of JPY 85.75.
お知らせ • May 22Ribomic Inc. Announces Completion of Its Phase I Trial of RBM-007 for the Treatment of AchondroplasiaRibomic Inc. announced the completion of its Phase I study of RBM-007 for the treatment of achondroplasia. The study results will be reported after a detailed analysis of the trial data. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
Reported Earnings • May 16Full year 2021 earnings released: JP¥46.16 loss per share (vs JP¥53.62 loss in FY 2020)Full year 2021 results: Net loss: JP¥1.19b (loss widened 39% from FY 2020). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥9.49 loss per share (vs JP¥15.71 loss in 3Q 2020)Third quarter 2021 results: Net loss: JP¥265.0m (loss widened 4.7% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Feb 11Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and DevelopmentRibomic Inc. and ASKA Pharmaceutical Co., Ltd. announced that they executed a multi-year joint research and development agreement for drug discovery research and development targeting specific hormone receptors with the aim of discovering new drugs. In this research, they concluded this agreement due to matching the intention of RIBOMIC, a medical discovery platform bio-venture, developing aptamer which is a kind of Nucleic Acid medicines, and ASKA holding the management vision of "becoming highly competitive specialty pharma company," and actively promoting the development based on new products. ASKA has been focusing on the development of pharmaceutical products for diseases in the field of obstetrics and gynecology, and aims to create aptamer pharmaceuticals that act on certain hormone receptors that play a crucial role in the field, by using RiboART System, RIBOMIC's basic drug discovery technology. With the conclusion of this agreement, ASKA will pay research expenditures to RIBOMIC on a step-by-step basis. RIBOMIC will also be entitled to an upfront payment for achievement of milestones in accordance with certain outcomes of the joint research. In addition, specific achievement conditions and amounts will not be disclosed under the contract. The impact of this transaction on RIBOMIC and ASKA's results for FY2020 will be minor.
お知らせ • Feb 02Ribomic Inc. Announces Completion of 50% of Enrollment of its Phase 2 Clinical Trial for Wet Age-Related Macular Degeneration (Tofu Study)Ribomic Inc. announced that it has completed subject enrollment of more than 50% of the ongoing Phase 2 trial (TOFU) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary. Despite COVID-19, RIBOMIC remains on track to complete TOFU by the end of 2021 as had been planned before the pandemic. In addition, the enrollment of the Phase 2 extension study (RAMEN) is also progressing well. Continued interest from clinical investigators in this extension study fueling the momentum required for the RAMEN study to also be completed by the end of 2021.
Is New 90 Day High Low • Dec 22New 90-day low: JP¥352The company is down 33% from its price of JP¥522 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.
お知らせ • Jun 29Ribomic Inc. to Report Q1, 2021 Results on Aug 07, 2020Ribomic Inc. announced that they will report Q1, 2021 results on Aug 07, 2020